Emapalumab-LZSG

Sobi has bought into Innate Pharma’s vision for lacutamab, handing the French biotech $75 million upfront for the rights to market the anti-KIR3DL2 antibody for an aggressive skin cancer. Innate has already secured a green light from the FDA to test lacutamab in the phase 3 Tellomak-3 study for cutaneous T-cell lymphoma (CTCL), ahead of a planned approval push in a subtype of CTCL called Sézary syndrome. The idea is that the study will be split between a confirmatory cohort for Sézary syndrome, which could support a potential accelerated approval for that indication, as well as a registrational cohort in mycosis fungoides, the most common subtype of CTCL. The company had been working out how it would fund the trial. Now, Sobi has swept in with the necessary upfront cash, as well as $40 million to potentially follow soon in near-term development milestones. In return, Sobi gets exclusive global rights to commercialize lacutamab for Sézary syndrome, assuming the phase 3 trial is a success. There’s also an additional $465 million in biobucks tied to Sobi’s option to expand its license to cover other indications like mycosis fungoides. Marseille-headquartered Innate has been keeping the faith in lacutamab’s ability to treat both Sézary syndrome and mycosis fungoides, despite the company scrapping plans to develop the drug for another skin cancer called peripheral T cell lymphoma in 2024 after lacutamab underperformed in a phase 1b trial . “We are thrilled to partner with Sobi and enable Tellomak-3 initiation, the pivotal next step in advancing lacutamab toward a potential accelerated approval in Sézary syndrome,” Innate CEO Jonathan Dickinson said in the release. “Sobi is the ideal partner to help unlock the full potential of lacutamab,” Dickinson added. “Their expertise in rare diseases, proven commercial capabilities and global reach perfectly complement Innate’s expertise in CTCL clinical development.” The upfront cash is expected to pave a cash runway through to the third quarter of 2027, which Innate hopes will be enough time to file an accelerated approval for lacutamab in Sézary syndrome. Innate had 25.4 million euros ($29.3 million) in the bank at the end of March, and said in this morning’s release that it would still “explore other financing opportunities” to fund additional priorities like its Nectin-4 exatecan antibody-drug conjugate IPH4502 and its AstraZeneca-partnered anti-NKG2A antibody monalizumab. Innate combined the announcement of the deal with news that the company’s head of clinical pharmacology Markus Jensen will be stepping up as chief medical officer. Jensen, a Bayer veteran, will be replacing Sonia Quaratino. Sobi is facing its own C-suite shakeup, with CEO Guido Oelkers, Ph.D., revealing last week that he will be taking on the top job at mRNA pioneer BioNTech. The Swedish biopharma’s commercial portfolio includes the thrombocytopenia medicine Doptelet, the Sanofi-partnered bleeding disorder drug Altuviiio and the ultra-rare hyperinflammation drug Gamifant. When it comes to cancer, Sobi markets the oral kinase inhibitor Vonjo for myelofibrosis and is also evaluating the therapy’s potential for chronic myelomonocytic leukemia. Oelkers branded today’s deal with Innate “an important step in strengthening our portfolio,” which “reflects our strategy of partnering with leading innovators to bring differentiated therapies to patients with rare diseases.”

Sobi's presentations highlight research across multiple rare diseases in haematology including PNH, ITP, HLH and myelofibrosis. STOCKHOLM, June 11, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that new clinical and real-world data will be presented at the 2026 Congress of the European Hematology Association (EHA2026), taking place June 11–14 in Stockholm, Sweden. The presentations include data across paroxysmal nocturnal haemoglobinuria (PNH), immune thrombocytopenia (ITP), primary haemophagocytic lymphohistiocytosis (HLH), and myelofibrosis. The data include real-world evidence and post hoc analyses for Aspaveli® (pegcetacoplan), Doptelet® (avatrombopag), Gamifant® (emapalumab), and Vonjo® (pacritinib). "As EHA comes to Stockholm this year, we are pleased to present new clinical and real-world evidence spanning multiple rare diseases," said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi. "These presentations reflect the breadth of our ongoing research across PNH, ITP, HLH and myelofibrosis, and continue to build understanding of treatment outcomes in areas of high unmet need." About Aspaveli®/Empaveli® (pegcetacoplan) Aspaveli/Empaveli (pegcetacoplan) is a targeted C3 and C3b therapy designed to regulate excessive activation of the complement cascade, part of the body's immune system, which can lead to the onset and progression of many serious diseases. Aspaveli/Empaveli is approved for the treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH) in the United States, European Union, and other countries globally. It is the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older approved in the United States, European Union, and other countries globally. About the Sobi® and Apellis (now part of Biogen) collaboration Apellis and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialisation rights for systemic pegcetacoplan. Apellis has exclusive U.S. commercialisation rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy. About Doptelet® (avatrombopag) Doptelet® is an orally administered thrombopoietin receptor agonist (TPO-RA) that increases platelet count. It is approved in the United States, European Union and Japan for thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure, and for ITP in adults according to local labeling. In the United States, Doptelet® is also approved for pediatric patients 1 year and older with persistent or chronic ITP who have had an insufficient response to a previous treatment. About Gamifant (emapalumab) Gamifant is the only approved anti-interferon gamma (IFNy) monoclonal antibody. Gamifant works by binding to and neutralising interferon gamma (IFNy). When interferon gamma (IFNy) is secreted in an uncontrolled manner, hyperinflammation occurs within the body. Gamifant is indicated for administration through intravenous infusion over one hour. Gamifant is approved in the US for the treatment of adult and paediatric patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. Gamifant is also approved in the US for the treatment of adult and paediatric patients with haemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in known or suspected Still's disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS . About Vonjo (pacritinib) Vonjo is a kinase inhibitor that is indicated in the US for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2 000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. Visiting address Norra Stationsgatan 93A, Stockholm +46 8 697 20 00 [email protected] This information was brought to you by Cision . The following files are available for download: 21% more press release views with Request a Demo